Collegium Pharmaceutical, Inc. (COLL)
22.75
-0.17
(-0.74%)
USD |
NASDAQ |
Sep 11, 16:00
22.76
0.00 (0.00%)
After-Hours: 20:00
Collegium Pharmaceutical Enterprise Value : 1.808B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 1.808B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.828B |
| September 08, 2026 | 1.828B |
| September 04, 2026 | 1.833B |
| September 03, 2026 | 1.839B |
| September 02, 2026 | 1.858B |
| September 01, 2026 | 1.849B |
| August 31, 2026 | 1.868B |
| August 28, 2026 | 1.892B |
| August 27, 2026 | 1.928B |
| August 26, 2026 | 1.963B |
| August 25, 2026 | 1.961B |
| August 24, 2026 | 1.957B |
| August 21, 2026 | 1.950B |
| August 20, 2026 | 1.964B |
| August 19, 2026 | 2.003B |
| August 18, 2026 | 1.995B |
| August 17, 2026 | 1.981B |
| August 14, 2026 | 1.986B |
| August 13, 2026 | 1.983B |
| August 12, 2026 | 1.904B |
| August 11, 2026 | 1.913B |
| August 10, 2026 | 1.953B |
| August 07, 2026 | 2.026B |
| Date | Value |
|---|---|
| August 06, 2026 | 2.015B |
| August 05, 2026 | 2.230B |
| August 04, 2026 | 2.230B |
| August 03, 2026 | 2.225B |
| July 31, 2026 | 2.219B |
| July 30, 2026 | 2.238B |
| July 29, 2026 | 2.248B |
| July 28, 2026 | 2.235B |
| July 27, 2026 | 2.223B |
| July 24, 2026 | 2.213B |
| July 23, 2026 | 2.225B |
| July 22, 2026 | 2.197B |
| July 21, 2026 | 2.234B |
| July 20, 2026 | 2.224B |
| July 17, 2026 | 2.241B |
| July 16, 2026 | 2.247B |
| July 15, 2026 | 2.262B |
| July 14, 2026 | 2.207B |
| July 13, 2026 | 2.200B |
| July 10, 2026 | 2.213B |
| July 09, 2026 | 2.232B |
| July 08, 2026 | 2.233B |
| July 07, 2026 | 2.253B |
| July 06, 2026 | 2.286B |
| July 02, 2026 | 2.272B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.191B |
| Zevra Therapeutics, Inc. | 492.62M |
| Supernus Pharmaceuticals, Inc. | 2.090B |
| Indivior Pharmaceuticals, Inc. | 4.357B |
| Crinetics Pharmaceuticals, Inc. (DELISTED) | 7.830B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.05M |
| Revenue (Quarterly) | 199.88M |
| Total Expenses (Quarterly) | 214.93M |
| EPS Diluted (Quarterly) | -0.4637 |
| Gross Profit Margin (Quarterly) | 55.18% |
| Profit Margin (Quarterly) | -7.53% |
| Earnings Yield | 5.43% |
| Operating Earnings Yield | 18.80% |
| Normalized Earnings Yield | 7.091 |